Clear cell carcinoma of the ovary: A retrospective multicentre experience of 254 patients with complete surgical staging

British Journal of Cancer

Volumn 94, Issue 10, 2006, Pages 1369-1374

  Takano, M ^a,k   Kikuchi, Y ^a   Yaegashi, N ^b   Kuzuya, K ^c   Ueki, M ^d   Tsuda, H ^a,e   Suzuki, M ^f   Kigawa, J ^g   Takeuchi, S ^h   Moriya, T ⁱ   Sugiyama, T ^j  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d OSAKA MEDICAL COLLEGE   (Japan)

^e OSAKA CITY GENERAL HOSPITAL   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g TOTTORI UNIVERSITY   (Japan)

^h Kobe Tokushukai Hospital   (Japan)

ⁱ TOHOKU UNIVERSITY HOSPITAL   (Japan)

^j IWATE MEDICAL UNIVERSITY   (Japan)

^k HAMMERSMITH HOSPITAL   (United Kingdom)

more..

Author keywords

Chemotherapy; Clear cell carcinoma; Lymph node metastasis; Ovary; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; MITOMYCIN C; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; ASCITES FLUID CYTOLOGY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; JAPAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL CAVITY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33646828032     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603116     Document Type: Article

References (32)

1. Adachi S, Ogasawara T, Yamasaki N, Shibahara H, Kanazawa R, Tsuji Y, Takemura T, Koyama K (1999) A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Jpn J Clin Oncol 29: 434-437
2. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC (1998) Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 70: 255-258
3. Bray F, Loos AH, Tognazzo S, La Vecchia C (2005) Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 113: 977-990
4. Cass I, Li AJ, Runowicz CD, Fields AL, Goldberg GL, Leuchter RS, Lagasse LD, Karlan BY (2001) Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 80: 56-61
5. Crozier MA, Copeland LJ, Silvia EG, Gershenson DM, Stringer CA (1989) Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol 35: 199-203
6. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW (2005) Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97: 1407-1427
7. Enomoto T, Kuragaki C, Yamasaki M, Sugita N, Otsuki Y, Ikegami H, Matsuzaki N, Yamada T, Wakimoto A, Murata Y (2003) Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 22: 447 (abstract 1797)
8. Ho CM, Chien TY, Shih BY, Huang SH (2003) Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol 88: 394-399
9. Ho CM, Huang YJ, Chen TC, Huang SH, Liu FS, Chang Chien CC, Yu MH, Mao TL, Wang TY, Hsieh CY (2004) Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 94: 197-203
10. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N (2002a) Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100: 281-287
11. Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S, Kanamori Y, Terakawa N (2002b) Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 93: 723-728
12. Jenison EL, Montag AG, Griffiths CT, Welch WR, Lavin PT, Greer J, Knapp RC (1989) Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 32: 65-71
13. Kanazawa K, Suzuki T, Tokashiki M (1999) The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival. Gynecol Oncol 73: 237-241
14. Kennedy AW, Biscotti CV, Hart WR, Webstar KD (1989) Ovarian clear cell adenocarcinoma. Gynecol Oncol 32: 342-349
15. Kikuchi Y, Hirata J, Ishii K, Kita, Nagata I (1998) Complexity of cis-diamminedichloroplatinum (II) resistance mechanisms in human ovarian cancer cells. In The Mechanism of Cisplatin Resistance and its Circumvention, Kikuchi Y (ed) pp 157-174. New York: Nova Science Publisher, Inc
16. Kita T, Kikuchi Y, Kudoh K, Takano M, Goto T, Hirata J, Tode T, Nagata I (2000) Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep 7: 327-331
17. Leitao Jr MM, Boyd J, Hummer A, Olvera N, Arroyo CD, Venkatraman E, Baergen RN, Dizon DS, Barakat RR, Soslow RA (2004) Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol 28: 147-159
18. Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Suzuki T, Ino K, Kawai M, Mizutani S (2003) Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture. Oncology 65: 29-36
19. Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P, Pomel C, Lhomme C, Duvillard P, Castaigne D (2003) Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 197: 198-205
20. Negishi H, Takeda M, Fujimoto T, Todo Y, Ebina Y, Watari H, Yamamoto R, Minakami H, Sakuragi N (2004) Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer. Gynecol Oncol 94: 161-166
21. O'Brien MER, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E (1993) Clear cell epithelial ovarian carcinoma cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 49: 250-254
22. Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M, Matsumoto K, Taketani Y (1998) Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. Cancer 83: 1555-1560
23. Sakuragi N, Yamada H, Oikawa M, Okuyama K, Fijino T, Sagawa T, Fujimoto S (2000) Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0). Gynecol Oncol 79: 251-255
24. Schiller W (1939) Mesonephroma ovarii. Am J Cancer 35: 1-21
25. Serov SF, Scully RE, Sobin LH (1973) International histologic classification of tumors. In Histologic Typing of Ovarian Tumors, Vol. 9. Geneva: World Health Organization
26. Shimizu Y, Umezawa S, Hasumi K (1998) A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore 27: 650-656
27. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K (2000) Clinical characteristics of clear cell carcinoma of the ovary. Cancer 88: 2584-2589
28. Takeshima N, Hirai Y, Umayahara K, Fujiwara K, Takizawa K, Hasumi K (2005) Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. Gynecol Oncol 99: 427-431
29. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95: 113-125
30. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y, Hirohashi S (2003) Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163: 2503-2512
31. Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ, Mok SC (2005) Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinoma by cDNA microarray analysis. Clin Cancer Res 11: 6880-6888
32. Yoonessi M, Weldon D, Satchidand SK, Crikard K (1984) Clear cell ovarian adenocarcinoma. J Surg Oncol 27: 289-297